isoxazoles has been researched along with zirconium in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dongen, GA; Hooge, MN; Jensen, MR; Jong, JR; Korte, MA; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; Vries, EG | 1 |
de Jong, JR; de Korte, MA; de Vries, EG; den Dunnen, WF; Garcia-Echeverria, C; Hollema, H; Jensen, MR; Lub-de Hooge, MN; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; van Dongen, GA | 1 |
Akimov, M; Banerji, U; Bongaerts, AH; Brouwers, AH; Chua, S; de Vries, EG; Fernandez-Ibarra, C; Gaykema, SB; Lub-de Hooge, MN; Oude Munnink, TH; Schröder, CP; Swanton, C; Vitfell-Rasmussen, J | 1 |
de Vries, EGE; Giesen, D; Kol, A; Lub-de Hooge, MN; Pool, M; Terwisscha van Scheltinga, AGT | 1 |
4 other study(ies) available for isoxazoles and zirconium
Article | Year |
---|---|
(89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Mice; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radioisotopes; Receptor, ErbB-2; Resorcinols; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zirconium | 2010 |
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Immunohistochemistry; Isoxazoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Resorcinols; Tissue Distribution; Vascular Endothelial Growth Factor A; Zirconium | 2010 |
89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radioisotopes; Resorcinols; Zirconium | 2014 |
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Feasibility Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Positron-Emission Tomography; Proto-Oncogene Proteins c-met; Radioisotopes; Resorcinols; Up-Regulation; Zirconium | 2017 |